An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options
CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation if certain conditions are met.
Rozlytrek should only be reimbursed to treat patients who have previously failed on all standard treatments for their current tumour site and who will be able to tolerate the treatment.
Rozlytrek should only be reimbursed as a single-agent therapy and should not be initiated in patients who have primary CNS tumours or those who have received prior treatment with an NTRK inhibitor.
Evidence demonstrated that Rozlytrek improves disease control, has a manageable toxicity profile, and may meet the needs of patients with no other effective treatment options. Based on CADTH’s assessment of the health economic evidence, Rozlytrek does not represent good value to the health care system at the public list price. A price reduction is therefore required. Based on public list prices, Rozlytrek is estimated to cost the public drug plans approximately $154 million over the next 3 years if testing costs are included. If testing costs are excluded, the budget impact drops to approximately $31 million over the next 3 years.
Solid tumours with an NTRK gene fusion are cancers that produce a protein called tropomyosin receptor kinase that speeds up tumour growth. NTRK fusions have been reported in many different types of solid tumours, including sarcomas and breast, colorectal, gynecological, bile duct, pancreas, lung, brain, salivary gland, and thyroid cancers, with the frequency of NTRK gene fusion varying across these tumour types.
There are no effective treatments for patients with advanced or metastatic extracranial solid tumours who have an NTRK gene fusion and who have previously failed on all standard treatments for their current tumour site. Jurisdictions may need to consider a common approach to NTRK fusion–testing strategies to ensure equitable patient access.
Treatment with Rozlytrek is expected to cost approximately $8,008 per patient per 28 days.
The CADTH pCODR Expert Review Committee (pERC) recommends that entrectinib be reimbursed for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation only if the conditions listed in Table 1 are met.
A pooled analysis of 3 open-label, single-arm trials (N = 121 and N = 193 for the efficacy and safety populations, respectively) demonstrated that entrectinib-treated adults with extracranial solid tumours (excluding primary central nervous system [CNS] tumours) that harbour an NTRK gene fusion exhibited a clinically important objective response rate (ORR) of 61.2% (95% confidence interval [CI], 51.9% to 69.9%). The median time to response was 1 month (95% CI, 0.9 to 1.0), and the median duration of response (DOR) was 20 months (95% CI, 13.0 to 38.2). Among patients with CNS metastases at baseline (N = 19), the intracranial ORR was 52.6% (95% CI, 28.9% to 75.6%), with a median intracranial DOR of 17.2 months (95% CI, 7.4 to not estimable [NE]). There was considerable heterogeneity in the antitumour activity of entrectinib on tumours in different sites and substantial uncertainty in the magnitude of the observed response rate and longer-term effects of entrectinib on patients’ survival and health-related quality of life (HRQoL). However, the committee acknowledged that tumours with an NTRK gene fusion are rare, which makes the collection of evidence particularly challenging; the correspondingly small numbers of patients in the included studies contributes to the uncertainty in the clinical evidence available to assess the effects of entrectinib.
pERC also considered that the patients for whom entrectinib is indicated often have a substantial burden of disease and no other treatment options. Although the response to entrectinib treatment varied considerably across different tumour sites, pERC evaluated the available evidence from a tumour-agnostic perspective. pERC concluded that the benefits demonstrated in certain types of tumours outweighed the absence of definitive clinical evidence in other tumour types. pERC also noted that entrectinib may meet the needs of patients with no other effective therapeutic options because it can control disease symptoms, provides disease control, has a manageable toxicity profile, and is relatively easy to administer.
Using the sponsor-submitted price for entrectinib and publicly listed prices for all other drug costs, the pooled incremental cost-effectiveness ratio (ICER) for entrectinib was $1,272,991 per quality-adjusted life-year (QALY) gained compared with standards of care across all relevant tumour types. This ICER assumes no testing costs and no additional treatment costs if the therapy fails. If testing costs are included, then the ICER increases to $16,746,589 per QALY gained. At these ICERs, entrectinib is not cost-effective at a willingness-to-pay threshold of $50,000 per QALY gained in the Health Canada–indicated population. A price reduction is therefore required.
Reimbursement Conditions and Reasons.
Entrectinib is an inhibitor of tyrosine receptor kinases A, B, and C (TRKA, TRKB, and TRKC) (encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively), proto-oncogene tyrosine-protein kinase ROS (ROS1; encoded by the gene ROS1), and anaplastic lymphoma kinase (ALK; encoded by the gene ALK). Entrectinib is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have an NTRK gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options. Entrectinib received Notice of Compliance with conditions (NOC/c) for this indication on February 10, 2020, from Health Canada pending the results of new information to verify its clinical benefit. The sponsor’s reimbursement request is per the Health Canada–approved indication.
The product monograph states that a validated assay is required for the selection of patients with NTRK fusion–positive unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases. NTRK fusion–positive status should be established before initiation of entrectinib therapy.
Entrectinib is available as 100 mg and 200 mg capsules. The recommended dose is 600 mg orally once daily. From the starting dose of 600 mg once daily, the dose can be reduced twice if needed to manage adverse events (e.g., first to 400 mg once daily and then to 200 mg once daily). It is recommended in the product monograph that patients are treated until disease progression or unacceptable toxicity. Health Canada has not authorized an indication for entrectinib for pediatric use, and there are no recommendations in the product monograph regarding dosing in pediatrics.
To make their recommendation, the committee considered the following information:
The literature on ethical issues related to tumour-agnostic therapies and their evaluations of effectiveness via basket trials, and the use of genetic testing (companion diagnostic or otherwise) to identify people living with NTRK fusion–positive solid tumours were reviewed to identify ethical considerations related to the use of entrectinib.
Four patient groups provided input into CADTH’s review: the Ontario Lung Association or Lung Health Foundation; Lung Cancer Canada; Colorectal Cancer Canada; and the Canadian Breast Cancer Network. All of the groups obtained information to support their input through surveys. Patient groups expressed the need for treatments that could extend progression-free survival (PFS), delay disease progression, relieve cancer-related symptoms, improve quality of life, and minimize side effects from treatment. Also, patients wish to reduce the impact of cancer on their ability to care for children and dependents, continue working, spend time with loved ones, participate in social activities, travel, maintain friendships, and pursue personal interests. Similar to the clinicians who provided input to CADTH, the patient groups highlighted inconsistency across Canadian jurisdictions with access to NTRK fusion testing. Patients emphasized a desire for NTRK fusion testing to be available earlier with the hope of avoiding exposure to alternative treatments that may be less effective and associated with more adverse events than an NTRK-targeting therapy. The input from 3 patient groups included information documenting the positive experience of patients with 3 different cancer types who had NTRK gene fusion and received treatment with entrectinib.
A panel of 3 clinical oncologists from across Canada provided input for this review. Because entrectinib is approved for use in a manner that is independent of tumour histology (with the exception of primary CNS tumours), each of the clinicians on the review team has expertise in the diagnosis and management of different types of primary tumours. The clinicians consulted by CADTH felt that it was difficult to fully characterize the unmet need for patients who could be eligible for treatment with entrectinib. This is due to the breadth of potential advanced solid tumours that may harbour NTRK fusion mutations and variability with the availability and effectiveness of potential alternative therapies. However, they agreed that, in the case of metastatic solid malignancies, virtually all patients eventually progress on currently available therapies, with the possible exception of select patients receiving immunotherapies for select cancer types.
The clinicians noted that the appropriateness of recommending that patients try other treatments before initiating treatment with entrectinib would depend on the cancer subtype and efficacy of front-line therapy. Similar to the patient group input, the clinical experts consulted by CADTH agreed that NTRK-targeting therapies, such as entrectinib, should be considered early in the course of NTRK fusion cancer treatment. This was based on the following rationale:
Treatments targeting the tumour as opposed to the NTRK fusion may be less effective and potentially more toxic than an NTRK-targeted therapy (i.e., entrectinib or larotrectinib), particularly for tumours for which the alternative is chemotherapy. All clinicians noted that there is considerable variability with access to NTRK fusion testing across tumour sites and across different Canadian jurisdictions. A targeted therapy, such as entrectinib, would be identified as a potential treatment option depending on whether the tumour is routinely tested for NTRK fusion and the timing of the testing.
The clinicians noted that, in adults, objective response, non-progression, patient-reported improvements in their ability to perform activities, improved survival, stabilization, improvement or reduced severity of symptoms, and improvement or no deterioration in quality of life would all be considered clinically meaningful outcomes. Clinicians noted that treatment response is typically assessed every 3 months; this interval may be prolonged once response is established or remission is achieved. The clinicians noted that treatment failure would be determined by disease progression, treatment intolerability, poor quality of life (e.g., poor performance status), or patient request to discontinue treatment.
Five clinician groups provided input for this review, including Lung Cancer Canada and the Lung Cancer, Breast Cancer, Gastrointestinal Cancer, and Head, Neck, and Thyroid Cancer Drug Advisory Committees from Ontario Health – Cancer Care Ontario. The input from the clinician groups was similar to the input from the clinical experts consulted by CADTH with respect to the unmet medical needs for adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have an NTRK gene fusion without a known acquired resistance mutation and with no satisfactory treatment options. The clinician groups also noted that the place in therapy for entrectinib would vary depending on the tumour site and the availability of safe and effective alternative therapies and the timing of access to NTRK fusion testing. Input regarding important end points, timing and criteria for evaluation, and likely discontinuation criteria were the same as the experts consulted by CADTH.
Input was obtained from the drug programs that participate in the CADTH reimbursement review process. The following were identified as key factors that could potentially affect the implementation of a CADTH recommendation for entrectinib:
The clinical experts consulted by CADTH provided advice on the potential implementation issues raised by the drug programs.
Responses to Questions From the Drug Programs.
The submission for entrectinib was based on a pooled analysis of 3 multi-centre, open-label, single-arm trials of entrectinib in adults with advanced or metastatic solid tumours: ALKA (phase I), STARTRK-1 (phase I), and STARTRK-2 (ongoing phase II basket trial). The primary evaluation for the pooled analysis was based on a clinical cut-off date (CCOD) of May 31, 2018, which was subsequently updated with larger sample sizes and longer follow-up (October 31, 2018, and August 31, 2020). The CADTH report reflects the most recent analysis available (CCOD: August 31, 2020).
The pooled analysis for the August 31, 2020, CCOD consisted of the following datasets:
Nearly all patients in the pooled analysis were from the STARTRK-2 trial in which patients received entrectinib at the dosage recommended in the Canadian product monograph (i.e., starting dosage of 600 mg once daily with up to 2 dose reductions permitted to manage adverse events).
The primary outcomes in the pooled analysis were ORR, defined as the proportion of patients with a best overall response of either complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumours 1.1 (RECIST Version 1.1) and determined by a BIRC; DOR; and best objective response. Secondary efficacy end points in the pooled analysis included time to tumour response; clinical benefit rate, defined as the proportion of patients with CR, PR, or stable disease for at least 6 months; PFS; and overall survival (OS). In addition, the sponsor pre-specified the following intracranial efficacy end points that were evaluated in the pooled subset of patients who had CNS metastases at baseline: intracranial ORR, intracranial DOR, and intracranial PFS. HRQoL data were only evaluated in the STARTRK-2 trial and included change from baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), EORTC QLQ-LC13 for the subset of patients with non–small cell lung cancer (NSCLC), and the EORTC QLQ-CR29 for the subset of patients with metastatic colorectal cancer.
The NTRK efficacy-evaluable analysis set (N = 121) was 51.2% female with a mean age of 55.9 years (64.5% were younger than 65 years). The baseline ECOG performance status was 43.8% for 0, 47.1% for 1, or 9.1% for 2. The majority of patients had received some form of prior anticancer therapy (n = 97; 80.2%); 74 (61.2%) patients had received any prior radiotherapy and 103 (85.1%) patients had previous cancer surgery. Approximately 30.6% of patients did not have prior systemic anticancer therapy. For those with a history of prior systemic therapy, 28.9% had 1 line, 21.5% had 2 lines, 9.9% had 3 lines, and 5.8% had 4 lines of systemic therapy. The most frequent systemic prior anticancer therapy was chemotherapy (n = 88; 72.7%), followed by targeted therapy (n = 24; 19.8%), immunotherapy (n = 13; 10.7%), and hormonal therapy (n = 10; 8.3%).
The solid tumour types that were reported for at least 5% of the patients included sarcoma (n = 26; 21.5%), mammary analogue secretory carcinoma (n = 24; 19.8%), NSCLC (n = 22; 18.2%), thyroid cancer (n = 13; 10.7%), colon cancer (n = 10; 8.3%), and breast cancer (n = 7; 5.8%). Nearly all patients had metastatic disease at baseline (96.7%); the most common metastatic sites were lung (61.2%) and lymph nodes (55.4%). There were 19 (17.2%) patients with CNS metastases at baseline as assessed by BIRC, with 17 (14.0%) patients reporting prior radiotherapy of the brain.
Unless otherwise noted, the efficacy results are from the August 2020 CCOD.
ORR: In the NTRK efficacy-evaluable dataset, the ORR by BIRC was 61.2% (95% CI, 51.87% to 69.88%). A best objective response of CR or PR was demonstrated by 15.7% and 45.5% of patients, respectively. The point estimates for ORR ranged widely across tumour types and the Cis reflected a high degree of uncertainty for many tumour types. At least 1 patient demonstrated a response to treatment in each of the tumour types, with the exception of neuroblastoma (n = 1). The ORR for the larger subgroup populations were generally consistent with the results for the overall population; though a higher proportion of tumour response was reported for the patients with salivary mammary analogue secretory carcinoma tumours (20 of 24; 83.3% [95% CI, 62.6% to 95.3%]) and a lower proportion for those with colorectal carcinoma (2 of 10; 20% [95% CI, 2.5% to 55.6%]).
Intracranial ORR: The BIRC-assessed intracranial ORR was 52.6% (95% CI, 28.86% to 75.55%) and 63.6% (95% CI, 30.8% to 89.1%) for all patients with baseline CNS disease (10 of 19 responded) and those with measurable disease at baseline (7 of 11 responded), respectively. A subgroup analysis demonstrated similar results for those who had no prior brain radiotherapy or brain radiotherapy at least 6 months before the initiation of treatment (55.6%; 95% CI, 21.2% to 86.3%; n = 9) and those with prior brain radiotherapy within 6 months of initiating treatment with entrectinib (50.0%; 95% CI, 18.7% to 81.3%; n = 10).
Time to tumour response: The median time to objective response was 1.0 month (95% CI, 0.9 to 1.0) for the overall population and 1.3 months (95% CI, 0.9 to 2.8) for patients with CNS metastases at baseline.
DOR: The DOR among responders was 20.0 months (95% CI, 13.0 to 38.2). For the patients who demonstrated a CR or PR with entrectinib, responses that lasted at least 6, 12, 18, 24, 30, and 36 months were reported for 58 (78%), 46 (62%), 32 (43%), 20 (27%), 10 (14%), and 4 (5%) of patients. The event-free probability was 0.82 (95% CI, 0.73 to 0.91) at 6 months, 0.66 (95% CI, 0.55 to 0.77) at 12 months, 0.49 (95% CI, 0.37 to 0.61) at 24 months, and 0.39 (95% CI, 0.24 to 0.53) at 36 months.
Intracranial DOR: The intracranial DOR among responders was 17.2 months (95% CI, 7.4 to NE) and 22.1 months (95% CI, 7.4 to NE) for all patients with baseline CNS disease and those with measurable disease at baseline, respectively.
Clinical benefit rate: The clinical benefit rate was 63.6% (95% CI, 54.8% to 71.7%).
PFS: The median PFS was 13.8 months (95% CI, 10.1 to 19.9), with a total of 72 (59.5%) patients experiencing disease progression or death at the CCOD of August 31, 2020. Updated subgroup analyses for PFS were not reported for the August 2020 CCOD.
Intracranial PFS: The median PFS was 10.1 months (95% CI, 6.3 to 26.7) with a total of 13 (68.4%) patients experiencing CNS disease progression or death at the August 2020 CCOD (5 progressive disease [PD] events and 8 deaths).
OS: The median OS was 33.8 months (95% CI, 23.4 to 46.4), and a total of 49 (40.5%) patients had died by the August 2020 CCOD. For patients with CNS metastases at baseline, the median OS was 19.9 months (95% CI, 7.9 to NE), with 50.2% patients having died by the August 2020 CCOD.
Nearly all NTRK fusion–positive patients experienced at least 1 adverse event (99.5%), 46.1% of patients experienced at least 1 serious adverse event, and 69.4% of patients experienced at least 1 grade 3 or higher adverse event. The proportion of patients with an adverse event leading to dose interruption or dose reduction was 54.4% and 26.9%, respectively. The proportion of patients with an adverse event leading to discontinuation was 14.5%.
The product monograph for entrectinib provides detailed recommendations for the management of adverse events that require temporary interruption, dose reduction, or discontinuation of treatment with entrectinib. The clinical experts consulted by CADTH indicated that those recommendations are a reasonable reflection of how patients would be managed in clinical practice. The product monograph also includes black box warnings that the drug may cause congestive heart failure and may cause fetal harm when administered to a pregnant woman. The clinical experts consulted by CADTH noted that patients would likely be screened and monitored for risk factors and symptoms related to heart failure before treatment and during follow-up visits while on treatment. Overall, the clinical experts consulted by CADTH agreed that the safety and tolerability of entrectinib was reasonable.
Due to the rarity of NTRK fusion cancers, the sponsor conducted pooled analyses of efficacy and safety for the basis of the regulatory and reimbursement review submissions. Although the pooled analyses included patients from 3 trials, nearly all of the patients were from the STARTRK-2 trial (98% and 97% in the efficacy and safety analyses sets, respectively). This reduces the potential uncertainty that can arise from between-study heterogeneity (e.g., differences in study design, objectives, phases, outcome measures, and eligibility criteria across trials) that was previously noted by CADTH for larotrectinib. Despite the use of pooled analyses, the sample sizes for each individual cancer type were too small, as would be expected due to the low prevalence of NTRK gene fusions (9 of 14 tumour types contained fewer than 10 patients), and the consequent 95% CIs were too wide to evaluate the consistency of the effect of entrectinib on different tumour types.
The efficacy end points were evaluated using BIRC-assessed outcomes for the primary analyses (with investigator-assessed outcomes provided as a sensitivity analysis); this is an important design feature because the trials were all open-label, single-arm studies. DCR, PFS, and OS are important end points for evaluating the efficacy of cancer treatments; however, these cannot be interpreted in the absence of a control group. In addition, a number of survival outcomes (PFS, OS, and DOR) were analyzed using the Kaplan-Meier method to pool data across the 3 trials, which could be problematic because traditional survival analysis methods, such as Kaplan-Meier curves, rely on the assumption that a single survival distribution can be used to estimate the survival outcome for all patients included in the analysis. However, as noted previously, nearly all the patients were derived from a single trial (STARTRK-2), thereby limiting concerns about the pooled approach for survival analyses. The HRQoL analyses were conducted for only 1 of the trials (STARTRK-2) and were limited by the open-label administration of entrectinib, lack of comparator group, absence of statistical testing, and small sample size for the disease-specific instruments for patients with NSCLC (N = 12) and metastatic colorectal cancer (N = 7).
The patient population in the pooled analysis was considered to be a reasonable reflection of the target population in Canada (i.e., adults with NTRK fusion–positive, unresectable, locally advanced, or metastatic extracranial solid tumours). Not all solid tumour types were represented in the pooled analysis and the majority of tumour types had fewer than 10 patients, resulting in wide CIs within subgroup analyses and reducing confidence in the generalizability of the results. Patients included in the pooled analysis had an ECOG performance status of 0, 1, or 2. Nearly all patients in the pooled analysis received entrectinib at the dosage recommended in the Canadian product monograph (i.e., starting dosage of 600 mg once daily with up to 2 dose reductions permitted to manage adverse events).
There were no direct or indirect comparisons filed by the sponsor to evaluate the comparative efficacy and safety of entrectinib versus larotrectinib or other alternative therapies.
No studies have directly compared entrectinib versus larotrectinib for patients with NTRK-positive tumours. The sponsor did not include an indirect comparison in their application to CADTH because they did not think it feasible to conduct a meaningful comparison due to the following challenges: NTRK fusions are only expressed in up to 1% of all solid tumours; patient enrolment in trials is low; and ongoing trials are single-arm, open-label, and with a study population with heterogeneous baseline characteristics (e.g., age, ECOG performance status, tumour site, presence of CNS metastases). In the absence of direct or indirect evidence comparing entrectinib and larotrectinib in the submission, CADTH conducted a literature search to identify any relevant published indirect comparisons and identified 1 matching-adjusted indirect comparison (MAIC) that compared entrectinib and larotrectinib in adults with NTRK gene fusion–positive tumours.
Garcia-Foncillas et al. (2022) conducted an MAIC to compare the efficacy and safety of entrectinib and larotrectinib in adults with NTRK fusion–positive tumours. The MAIC was funded by the manufacturer of larotrectinib; therefore, patient-level data were available for the larotrectinib-treated patients but not for entrectinib-treated patients. The data used for entrectinib were derived from the earlier May 31, 2018, and October 31, 2018, CCODs (i.e., a smaller sample size than the August 31, 2020, CCOD data included in the current submission to CADTH). Adult patients were selected for inclusion in the MAIC based on the presence of NTRK fusion, an ECOG performance status of 2 or less, and were NTRK inhibitor-naive. Patients were matched on the following baseline characteristics: sex, age, race, ECOG performance status, tumour type, metastatic disease (versus locally advanced, unresectable disease), NTRK fusion type, prior lines of systemic therapy for metastatic disease, and CNS metastases.
Garcia-Foncillas et al. (2022) reported that larotrectinib was associated with a statistically significantly greater duration of OS (hazard ratio [HR] = 0.43; 95% CI, 0.23 to 0.83; P < 0.05) and DOR (HR = 0.49; 95% CI, 0.25 to 0.98; P < 0.05) compared with entrectinib. The authors reported no statistically significant difference for PFS (HR = 0.66; 95% CI, 0.42 to 1.03; P = 0.07) or ORR (risk difference = 3.8; 95% CI, −11.7 to 19.3; P = 0.63). Results were similar in sensitivity analyses applying different specifications for the MAIC and using a simulated treatment comparison method.
There were no statistically significant differences reported between larotrectinib and entrectinib for serious treatment-related adverse events or treatment-related adverse events leading to discontinuation.
Several key details from the MAIC were not provided in the published study, which limits the ability to provide a critical appraisal. However, the primary limitation of the results is due to the unanchored nature of the comparison, which would require the inclusion of all prognostic factors and all effect modifiers to ensure unbiased results. Therefore, due to this limitation and others, firm conclusions based on the results of this MAIC are not recommended.
The sponsor provided the intrapatient comparison of efficacy from a single-arm trial of entrectinib in tumour-agnostic indications. The sponsor’s objective was to generate and analyze evidence for the comparative effectiveness of entrectinib by exploring the role of intrapatient comparison as an alternative to a traditional comparator arm.
Analyses were conducted on retrospectively collected data from the STARTRK-2 trial to generate intrapatient comparisons. There were 3 cohorts of patients based on their prior systemic therapy in the metastatic setting and presence or absence of documented progression.
A total of 71 patients with efficacy-evaluable NTRK fusion–positive disease who were enrolled in the STARTRK-2 trial up to April 30, 2018 (data cut-off October 31, 2018), were included in the analysis. Of 71 patients, 51 patients had received systemic therapy before commencing entrectinib (38 had documented PD and 13 had no documented PD on the most recent prior systemic therapy) and 20 patients had not received prior systemic therapy. Among those who had received prior systemic therapy, 21 (41.2%) received 1 line, 20 (39.2%) received 2 lines, and 10 (19.6%) received 3 or more lines of therapy. The treatment regimens varied greatly within and between tumour types. The most common tumour types were sarcoma (22.5%), NSCLC (16.9%), mammary analogue secretory carcinoma (16.9%), and thyroid cancer (9.9%).
The key analysis used was GMI as defined by the ratio of PFS on entrectinib to time to discontinuation (TTD) on the most recent prior therapy. TTD was chosen to measure efficacy of the prior therapy instead of time to progression due to the limited data available to reliably define a time to progression outcome. A GMI ratio of at least 1.3 was selected as the threshold to indicate a clinically meaningful benefit. Additional analyses explored TTD and ORR for entrectinib and prior systemic therapy.
For GMI in patients with PD on prior systemic therapy, median GMI was 2.53 (range, 0.09 to 61.5) with 25 (65.8%) patients having a GMI of at least 1.3. For GMI thresholds, 23 (60.5%) patients met the 1.5 or greater threshold, 23 (60.5%) patients met the 1.8 or greater threshold, and 22 (57.9%) patients met the 2.0 or greater threshold. Of 7 patients with a GMI less than 1.0, 4 (57.1%) patients were censored for PFS.
Kaplan-Meier survival analysis showed that the curves for PFS and TTD for entrectinib were similar (PFS to TTD: HR = 1.08; 95% CI, 0.6 to 1.9), with a median PFS of 11.2 months (95% CI, 6.7 to NE) and a median TTD of 9.9 months (94% CI, 7.3 to 14.8) on entrectinib. Both PFS and TTD on entrectinib were longer than TTD on most recent prior therapy, which was for a median of 2.9 months (95% CI, 2.0 to 4.9). The ORR for entrectinib was 60.5% (23 of 38; all PR) in patients with documented progression on prior therapy, 46.2% (6 of 13; all PR) in patients with no documented progression on prior therapy, and 80% (5 of 20 with CR and 11 of 20 with PR) in patients with no prior therapy.
The ORR for the most recent prior systemic therapy was 15.8% (6 of 38; 1 CR and 5 PR) in patients with documented progression on prior therapy and 7.7% (1 of 13; 1 PR) in patients with no documented progression on prior therapy.
In summary, the results show a longer PFS with entrectinib relative to the TTD with the last prior treatment; however, this observation relies on many assumptions, including the key assumption (TTD as a surrogate for PFS), which appears to be invalid based on the information provided about the calculation of the GMI. There was no formal investigation of differences in the GMI by tumour type or other patient characteristics, and the descriptive individual GMI results suggest large variations in the GMI. It is unclear how some of the presented results were obtained or if inferences made with them are valid given the intrapatient nature of the analysis. However, if the GMI can be considered a reliable comparison tool, it appears to support the case that entrectinib may be beneficial in many of the tumour types when other treatments have failed, which is the case across many patient characteristics, mitigating many of the concerns about patient heterogeneity other than tumour type. Without inference (the presented CI), a large variation in GMI is evident across the tumour types and remains a main limitation.
The sponsor provided a report comparing OS in patients with NTRK fusion–positive solid tumours who were treated with entrectinib in the sponsor’s clinical trials (pooled dataset) versus patients treated with standard of care from the Flatiron/FMI clinico-genomic database.
The Flatiron Health database is a US longitudinal database with de-identified data originating from approximately 280 cancer clinics and representing more than 2.8 million patients with cancer (the majority from community oncology settings). The Flatiron Health data platform aggregates and processes patient-level data.
Median weighted OS, both crude and matched was estimated via Kaplan-Meier survival curves. HRs were estimated using weighted univariate Cox proportional hazards models for patients treated with entrectinib compared with patients not treated with entrectinib. The index date for the end point analyzed was the start of entrectinib treatment for trial patients and the NTRK positive test report date for those who received standard of care.
The nearest-neighbour propensity score matching model with replacement was used to perform the matching, with each match first done within each tumour type observed in the NTRK fusion–positive population (direct match by tumour). Characteristics included in this analysis were tumour type/histology, age of patient, stage of cancer at diagnosis, number and type of previous treatments, and type of centre where patient was treated (academic versus community).
Before matching, the study population with the same tumour type consisted of | | patients who received standard of care and | | entrectinib-treated patients. Compared with the standard of care group, the entrectinib-treated group were younger (median age: | | |||||| ||||), included a higher proportion of women (|| ||||), were treated only in academic centres, and had a lower proportion of patients with a history of smoking (||||||||||||). Standard of care patients were more heavily treated at the index date (e.g., only | | had not received treatment before the index date versus | || of the entrectinib-treated patients) and were more likely to have stage IV disease at the time of initial diagnosis (||||||||||||). When the 2 cohorts were matched, the main analyses only included | | trial patients matched to | | standard of care patients, and only a moderate balance of cohorts could be achieved for the 4 variables selected a priori (|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||).
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||| ||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| ||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| ||||||||||||||||||||||||||||||||||||||||||||
The following important limitations prevent drawing firm conclusions based on the results of this analysis:
The results show a longer median OS with entrectinib compared with patients who received standard of care (|||||||||||||||||||||||||||||||||||] versus a weighted OS ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||). Important limitations with this analysis, including the small sample size and heterogeneity across treatment groups, prevent drawing firm conclusions.
Cost and Cost-Effectiveness.
Based on a CADTH reanalysis, the estimated budgetary impact of funding entrectinib, assuming no displacement of other treatment options, is expected to be $69,746,533 in year 1, $42,266,837 in year 2, and $42,005,060 in year 3, for a 3-year budget impact of $154,018,431 when testing costs are included. When including only drug costs, the budgetary impact of reimbursing entrectinib is expected to be $13,444,089 in year 1, $9,080,920 in year 2, and $8,435,525 in year 3, for a 3-year budget impact of $30,960,534. CADTH was unable to account for the potential displacement of alternate therapies or for the potential funding of larotrectinib. Should larotrectinib be funded before entrectinib, the budgetary impact of reimbursing entrectinib would be substantially reduced in terms of both incremental drug and NTRK fusion–testing costs.
Dr. Maureen Trudeau (Chair), Mr. Daryl Bell, Dr. Jennifer Bell, Dr. Matthew Cheung; Dr. Winson Cheung, Dr. Michael Crump, Dr. Leela John, Dr. Christian Kollmannsberger, Mr. Cameron Lane, Dr. Christopher Longo, Dr. Catherine Moltzan, Ms. Amy Peasgood, Dr. Anca Prica, Dr. Adam Raymakers, Dr. Patricia Tang, Dr. Marianne Taylor, and Dr. W. Dominika Wranik
Meeting date: September 14, 2022
Regrets: None
Conflicts of interest: None
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party supplier of information.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Redactions: Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines.
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options
Sponsor: Hoffmann-La Roche Ltd.
Recommendation: Reimburse with conditions
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
